<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cph8kex991090606.txt
<DESCRIPTION>PRESS RELEASE DATED AUGUST 15, 2006
<TEXT>

Contact:

Crocker Coulson                               Donald Xu
President                                     Vice President, Strategic Planning
CCG Elite                                     China Pharma Holdings, Inc.
310 231-8600 ext 103                          858-776-8880
crocker.coulson@ccgir.com                     dxu@chinapharmaholdings.com

FOR IMMEDIATE RELEASE

                           China Pharma Holdings, Inc.
                        Provides Preliminary 2007 Outlook

HAIKOU CITY, Hainan Province,  PRC - September 20, 2006 - China Pharma Holdings,
Inc. ("China Pharma") (OTC BB: CPHI.OB) today provided a preliminary outlook for
its 2007 financial results.

The  Company  previously  announced  that it expects to achieve  revenues of $20
million and net income of $8 million for the year ending  December 31, 2006. The
Company  expects  net  income  to  increase  by at least  30% for 2007 from 2006
levels.  This  guidance  is based on recent  new drug  introductions  and strong
pipeline development.

"China Pharma's  strategy of growth through  aggressive new product launches and
strong  research and  development  provides us  confidence  that we will sustain
improved net income for 2007. Recent product launches include  Propylgallate and
Ozagrel, which treat cardiovascular & cerebrovascular  conditions, the first and
third  leading  causes of death in China,  respectively,"  commented Li Zhi Lin,
President and CEO.

About China Pharma Holdings, Inc.

China Pharma  Holdings,  Inc.  develops,  manufactures,  and markets generic and
brand  bio-pharmaceutical   products  in  China  that  treat  a  wide  range  of
conditions, including infections,  hepatitis, vascular, CNS and other prevailing
diseases.   Helpson   Bio-pharmaceutical   Co.,  Ltd   (Helpson),   a  specialty
bio-pharmaceutical  company  headquartered  in Haikou City,  Hainan  province in
China, is a wholly owned subsidiary of China Pharma Holdings, Inc.

Safe Harbor  Statement  Under the Private  Securities  Litigation  Reform Act of
1995:  Any  statements  set  forth  above  that  are not  historical  facts  are
forward-looking statements that involve risks and uncertainties that could cause
actual  results  to  differ   materially  from  those  in  the   forward-looking
statements,  which  may  include,  but are  not  limited  to,  such  factors  as
unanticipated  changes  in product  demand,  increased  competition,  failure to
obtain or maintain  intellectual  property protection,  downturns in the Chinese
economy,  uncompetitive  levels of research and  development,  failure to obtain
regulatory  approvals,  and other information  detailed from time to time in the
Company's  filings and future  filings  with the United  States  Securities  and
Exchange Commission.

                                       ###
</TEXT>
</DOCUMENT>
